Presentation at the AASLD Annual Meeting in San Francisco, USA
Turnover of 5.9 million euros for the first nine months of 2008
IPH 4201 enters in pre-clinical validation
Financial and investor relations calendar for 2009
Vivalis and Innate Pharma sign a collaboration and commercial license agreement
Financial results for 2008
Milestone payment in IPH 24 project developed in collaboration with Novo Nordisk A/S
Operating revenue of 12.9 million Euros for the year 2008
